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Earlier work demonstrated that the transcription
factor C/EBPa can convert immature and mature
murine B lineage cells into functional macrophages.
Testing >20 human lymphoma and leukemia B cell
lines, we found that most can be transdifferentiated
at least partially into macrophage-like cells, provided
that C/EBPa is expressed at sufficiently high levels.
A tamoxifen-inducible subclone of the Seraphina
Burkitt lymphoma line, expressing C/EBPaER, could
be efficiently converted into phagocytic and quies-
cent cells with a transcriptome resembling normal
macrophages. The converted cells retained their
phenotype even when C/EBPa was inactivated,
a hallmark of cell reprogramming. Interestingly,
C/EBPa induction also impaired the cells’ tumorige-
nicity. Likewise, C/EBPa efficiently converted a
lymphoblastic leukemia B cell line into macro-
phage-like cells, again dramatically impairing their
tumorigenicity. Our experiments show that human
cancer cells can be induced by C/EBPa to trans-
differentiate into seemingly normal cells at high
frequencies and provide a proof of principle for
a potential new therapeutic strategy for treating B
cell malignancies.INTRODUCTION
The induction of differentiation as a therapeutic approach for
cancer had been suggested more than 3 decades ago. The
idea was largely based on the findings that erythroleukemic
cell lines can be induced to terminally differentiate with
compounds such as DMSO and hexamethylene bisacetamide
(HMBA), and myeloid leukemia cell lines with retinoids and
vitamin D (Nowak et al., 2009). Later, it was shown that adminis-
tration of all-trans retinoic acid to patients with acute promyelo-
cytic leukemia is very effective therapeutically, especially when
combined with the apoptosis-inducing compound arsenicCtrioxide (Waxman, 2000). Most recently, it was shown that
cancer stem cells of acute myeloid leukemia (AML) can be selec-
tively induced to differentiate using a drug that blocks dopamine
receptors, strongly inhibiting tumor formation in a xenograft
mouse model (Sachlos et al., 2012).
Attempts have also beenmade to force terminal differentiation
of AML cells with the bZip family transcription factor C/EBPa.
This factor is required for the formation of myelomonocytic cells
(Zhang et al., 2004), and C/EBPa mutations are associated with
a subset of AML (Pabst et al., 2001; Valk et al., 2004), suggesting
that C/EBPa may act as a tumor suppressor in myeloid cells.
In one study, it was shown that C/EBPa could convert CD34+
bone marrow-derived precursors from AML into more mature,
quiescent myeloid cells (Schepers et al., 2007). In another report,
the compound CDDO was found to induce the partial differen-
tiation of the myeloid cell line HL60 into granulocytes, by stabi-
lizing the expression of a C/EBPa isoform (Koschmieder et al.,
2009). However, neither of these studies assessed the tumori-
genic potential of the differentiated cells.
B cell malignancies encompass a wide variety of distinct
disease entities that include mature B cell lymphomas, B cell
acute lymphoblastic leukemia (B-ALL), Hodgkin lymphoma,
and multiple myeloma (Campo et al., 2011). Currently, chemo-
therapy, radiation, and anti-CD20 antibody treatment are the
mainstays of B cell lymphoma and leukemia treatment.
However, the fact that a substantial number of patients are
eventually not cured justifies the search for new and more effec-
tive therapeutic approaches (Shaffer et al., 2012). For example,
it has recently been shown that a combination of CD47 and
CD20 antibodies can abrogate the tumorigenicity of human
B cell lymphoma cells in immunodeficient mice (Chao et al.,
2010). In addition, small molecules that block BCL6 corepres-
sors have been developed and are effective in experimental
models of B cell lymphoma (Cerchietti et al., 2010). Other new
therapies include the exogenous administration of soluble tumor
suppressors (Oricchio et al., 2011). However, the differentiation
induction approach has so far not been applied to the therapy
of B cell neoplasms.
Our earlier work has shown that normal murine B cell precur-
sors as well as mature antibody-producing B cells can be
induced by C/EBPa to transdifferentiate into functional macro-
phages in vitro and in vivo (Xie et al., 2004). Using pre-B cellsell Reports 3, 1153–1163, April 25, 2013 ª2013 The Authors 1153
Table 1. Responsiveness of B Cell Lymphoma and Leukemia Cell Lines to C/EBPa
Cell Line
Changes in Cell Surface
Antigen
Dose Dependence C/EBPa Protein SummaryMac-1 CD19
B-ALL RCH-ACV [[[ YYY yes ++ 1/5 R,
2/5 PR,
2/5 NR
CEMO-1 no effect no effect n.r. +/
Val [ Y yes +/
MUTZ5 no effect YY yes –
NALM-20 no effect no effect n.r. –
ABC-DLBCL SU-DHL8 no effect no effect n.r. – 2/4 PR,
2/4 NRU-2932 [ Y yes +++
HLY1 no effect no effect n.r. –
HBL1 [ no effect yes –
GCB-DLBCL Sc-1 no effect Y yes +/ 4/4 PR
DB no effect Y yes +/
DoHH2 [ Y yes +
SU-DHL6 no effect YY yes +/
MCL G519 [ YY yes +/ 4/4 PR
JeKo-1 no effect YY yes –
Z138 no effect YY yes ++
HBL2 no effect YY yes –
SMZL VL51 [ no effect yes – 1/1 PR
BL Seraphina [[ YY yes ++ 5/5 PR
Raji [ no effect yes ++
Daudi no effect YY yes +++
CA46 no effect Y yes ++
Namalwa no effect YY yes ++
The table shows the results obtained after induction of C/EBPa in B cell lymphoma and leukemia cell lines using E2 (BL lines) or doxycycline (B-ALL,
ABC-DLCL, GCB-DLBCL, MCL, SMZL). Time of analysis for differentiation antigens was 4, 6, or 8 days p.i. Dose dependence wasmeasured gating on
different levels of the GFP or Tomato expression detected by FACS. C/EBPa levels were detected by western blot. The number of arrows indicates
the range of cells that changes phenotype, with one arrow indicating at least 10%, two arrows at least 30%, and three arrows at least 70%. n.r., not
relevant; R, responder; PR, partial responder; NR, nonresponder; B-ALL, acute lymphoblastic leukemia; ABC-DLBCL, activated B cell-like diffuse
large B cell lymphoma; GCB-DLBCL, germinal center B cell-like diffuse large B cell lymphoma; MCL, mantle cell lymphoma; SMZL, splenic marginal
zone lymphoma; BL, Burkitt lymphoma. See also Figure S1.containing a fusion of C/EBPa with the estrogen receptor
hormone binding domain (C/EBPaER), essentially all cells can
be converted into functional macrophage-like cells following
treatment with 100 nM 17b-estradiol (E2) (Bussmann et al.,
2009). Here, we demonstrate that C/EBPa can likewise convert
at high efficiencies selected human B cell lymphoma and
leukemia cell lines into macrophage-like cells, impairing the
cells’ tumor-forming capacity. These findings show that cells of
human origin can be reprogrammed at high efficiencies,
providing a proof of principle for the concept that lymphoid-to-
myeloid lineage transdifferentiation may represent a new thera-
peutic strategy for B cell neoplasms.
RESULTS
Expression of C/EBPa in a Panel of Lymphoma
and Leukemia Cell Lines Induces Changes
in Differentiation Antigens
To determine whether C/EBPa can induce the transdifferentia-
tion of malignant B cells into macrophages, 23 cell lines derived1154 Cell Reports 3, 1153–1163, April 25, 2013 ª2013 The Authorsfrom patients with various B cell lymphoma and leukemia
subtypes were screened for their susceptibility of conversion
intomacrophages, using twoC/EBPa induction strategies (Table
1). The first strategy consisted of infecting cells with a retrovirus
vector containing C/EBPaER-GFP. To activate C/EBPa, the cells
are treated with E2, which mediates the proteins’ translocation
into the nucleus. In the second strategy, cell derivatives stably
expressing rtTA are infected with a retrovirus that expresses
TetO-C/EBPa and can be activated by 2 mg/ml doxycycline,
and containing tdTomato as an indicator of infection. Treatment
of the various cell lines produced with these two strategies with
either E2 or doxycycline revealed only one line (RCV-ACH)
showing an essentially complete upregulation of Mac-1 and
downregulation of CD19 antigens. Among the rest, 4 did not
respond at all, and 18 responded partially, with 15 predominantly
downregulating CD19, and 8 exhibiting small proportions of
Mac-1-positive cells. To assess whether CD19 downregulation
is an adequate indicator of partial transdifferentiation, we used
quantitative RT-PCR (qRT-PCR) to monitor the changes in
gene expression of a panel of B cell and macrophage-restricted
genes in nine of the partially responding cell lines. Specifically,
we tested the expression of the B cell markers CD19, CD79A,
IGJ, IGLL1, VPREB3, and EBF1, and the macrophage markers
ITGAM (MAC-1), CD14, CSFR1, FCGR1B, and MMP9. Fig-
ure S1A shows representative plots of changes in gene expres-
sion of three partially responding cell lines (Z138, HBL2, and
Namalwa) at 2 and 4 days after induction. We detected the
downregulation of not only CD19 but also of most other B cell
genes tested, consistent with the idea that this antigen is an
appropriate indicator of B cell silencing. Interestingly, in all nine
induced cell lines, we also detected an upregulation of most
of the five macrophage genes interrogated, including Mac-1
(Figure S1A; data not shown). The reason for this apparent
discrepancy is probably that the Mac-1 mRNA was below the
levels needed for protein expression.
Importantly, cells with an altered expression of CD19 and/or
Mac-1 antigens were enriched in the fraction corresponding to
the highest level of the transgene, also showing that whereas
lower levels of C/EBPa are sufficient for B cell gene silencing,
higher levels are required for macrophage gene upregulation
(Figures S1B and S1C). A correlation between C/EBPa levels
and biological response was also observed by western blot
(Figure S1E). Thus, three of the four nonresponders exhibited
undetectable levels of C/EBPa protein, except for the cell line
CEMO1, which showed a faint C/EBPa band. Moreover, in
some lines, such as Daudi, the level of the reporter gene
decreased with time after induction, as did their changes in anti-
gens (Figure S1D), again supporting the idea that maintenance
of high levels of C/EBPa expression is critical for the full respon-
siveness of lymphoid cell lines.
BLaER1 Cells, Derived from the Burkitt Lymphoma Cell
Line Seraphina, CanBeConverted intoMacrophage-like
Cells at High Efficiencies
As a prototypic model of a mature B cell lymphoma, we decided
to study the Seraphina cell line. Again, described before, the
conversion efficiency of C/EBPaER-GFP-infected Seraphina
cells was found to be dose dependent (Figure S2A). To obtain
a robust and efficient switching system, we generated several
subclones and found, as expected, that two cloneswith relatively
high GFP and C/EBPa expression transdifferentiated best, as
determined by changes in differentiation antigens as well as in
size (forward scatter, FSC) and granularity (side scatter, SSC),
whereas the clone with the lowest GFP/C/EBPa expression
was nearly unresponsive (Figures 1A–1D). We chose the high-re-
sponding clone 1, thereafter termed BLaER1, for further studies.
After treatment with E2, >90% of the BLaER1 cells showed
a reciprocal regulation of CD19 and Mac-1 (Figures 1E and 1F),
whereas no changes were observed in uninduced controls or in
the original Seraphina cells treated with E2. The induced cells
became adherent, acquired an irregular morphology and asym-
metrically located nuclei, and developed F-actin-positive lamelli-
podia (Figure 1G). Similar changes were also seen in Seraphina
cells containing rtTA and the doxycycline-inducible C/EBPa
construct, after treatment with the inducer (Figure S2B).
We next analyzed the changes in gene expression during
transdifferentiation of BLaER1 cells, comparing uninduced
(0 hr) cells with cells treated with E2 for 3, 6, 9, 12, 18, 24, 36,C48, 72, 120, or 168 hr. Primary human B cells and macrophages
were used as controls. RNAs were analyzed by Agilent microar-
rays, detecting 34,800 unique transcription units, of which
4,900 showed a >4-fold change between any two samples for
at least one time point of treatment. A principal-component
analysis (PCA) of these probes showed that during the conver-
sion, the transcriptome of BLaER1 cells exhibited a trajectory
that starts in a position approximating that of peripheral blood
Bcells andends close to that of normalmacrophages (Figure 2B).
Closer inspection of the PCA results revealed that continuously
downregulated and upregulated genes contributed almost
exclusively to this outcome. Intermittently regulated genes
were only found after a cutoff below 2-fold, and these were not
further investigated. K-means clustering followed by heatmap
visualization of the genes with >4-fold changes confirmed these
findings (Figure 2A), again showing that the largest changes
throughout the time course occurred in genes that were either
continuously downregulated (2,548 probes) or upregulated
(2,353 probes). These were highly enriched for the Gene
Ontology (GO) terms ‘‘cell cycle’’ and ‘‘immune response,’’
respectively (Figure S3A). Further analyses of the expression
data confirmed that positive cell-cycle regulators such as cyclins
B1 (CCNB1) and A2 (CCNA2), aurora kinase A (AURKA), cancer
susceptibility candidate 5 (CASC5), and minichromosome-
deficient genes 7 and 10 (MCM7 and MCM10) were contained
in the group of downregulated genes. In addition, negative cell-
cycle regulators such as cyclin-dependent kinase inhibitor C
(CDKN1C, p57) and p16-INK4A and p19ARF (CDKN2A) were
found in the group of upregulated genes. Importantly, B cell
markers were exclusively contained in the downregulated
group, including CD19 and the B cell receptor components
immunoglobulin J (IGJ), CD79A, immunoglobulin lambda-like 1
(IGLL1), andVPREB3 (Figures 2Aand2C). In contrast, themacro-
phage markers ITGAM (MAC-1), the LPS receptor component
CD14, the receptor for macrophage colony-stimulating factor
(CSF1R), the high-affinity Fc gamma receptor 1b (FCGR1B),
the matrix metallopeptidase 9 (MMP9), and other macrophage
genes were in the group of upregulated genes (Figures 2A and
2D), reflecting the expression differences observed between
primary B cells and macrophages (Figure S3B). These findings
were confirmed by qRT-PCR and changes in CD79a and CD14
protein expression shown by FACS (Figures S3C and S3D). In
addition, the MYC oncogene, which is highly expressed in
Seraphina cells due to its juxtaposition to the IGH gene locus in
the chromosomal translocation t(8;14)(q24;q32) (Toujani et al.,
2009), became downregulated during transdifferentiation of
BLaER1 cells to levels seen in normal B cells and macrophages,
as detected both by mRNA and western blot analyses (Fig-
ure S2C). As expected, the reprogrammed cells retained the
IGH rearrangements of the original lymphoma cells (Figure S2D).
During Transdifferentiation, BLaER1 Cells Become
Phagocytic and Quiescent
To test whether the reprogrammed macrophages are functional,
BLaER1 cells were induced with E2 for 3 days and incubated
with E. coli labeled with dsRed. As illustrated in the micrographs
in Figure 3A, the induced cells ingested the bacteria, and a
quantitative analysis by FACS showed that 80% of the inducedell Reports 3, 1153–1163, April 25, 2013 ª2013 The Authors 1155
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Figure 1. Activation of a Hormone-Inducible Form of C/EBPa Converts BL-Derived Cells into Macrophage-like Cells
(A) FACS plots of three Seraphina cell-derived clones expressing C/EBPaER-GFP showing GFP expression (left panel) as well as C/EBPa expression by western
blot (right panel). The arrow indicates the C/EBPa band, and Ponceau staining of the proteins loaded is shown below.
(B) Mac-1 and CD19 expression of three Seraphina-derived clones 4 days after induction.
(C and D) FSC (C) correlating with size of the clones and SSC (D) correlating with granularity of the same cells shown in (A) and (B). Blue lines represent uninduced
cells (0 days), red lines represent 4 day induced cells.
(E) FACS profiles of BLaER1 cells treated with E2 and stained with antibodies against Mac-1 and CD19 at the times indicated.
(F) Kinetics of differentiation antigen expression as determined from the data shown in (E).
(G) Uninduced and induced cells were fixed and stained with phalloidin Alexa Fluor 568 to detect F-actin (shown in red) as well as with DAPI to visualize the nuclei
(shown in blue). Scale bar, 10 mm.
See also Figure S2.cells became phagocytic, whereas uninduced cells remained
negative (Figure 3B). Similar results were obtained with the yeast
Candida albicans, revealing the formation of filamental forms
inside the reprogrammed macrophages (Figures 3C and 3D).
We also noted that BLaER1 cell cultures converted into macro-
phages that were incubated overnight (O/N) with C. albicans
became cleared of yeast, whereas uninduced cells were over-
grown by the pathogen (data not shown), indicating a powerful
antimicrobial activity of the reprogrammed cells. During trans-
differentiation, the cells divided once in average and after
2 days, became quiescent without exhibiting significant pro-
portions of dead cells, whereas uninduced cells doubled
approximately every 48 hr (Figure 3E; data not shown). BrdU
incorporation assays combined with propidium iodide staining1156 Cell Reports 3, 1153–1163, April 25, 2013 ª2013 The Authorsconfirmed these findings, showing a gradual arrest upon E2
treatment at theG0/G1 stage of the cell cycle with no cycling cells
remaining after 2–3 days (Figure 3F). In addition, FACS analysis
did not reveal additional DNA peaks to those corresponding to
G0/G1 and G2/M, suggesting absence of both apoptotic and
polyploid cells (Figure S4A). These findings are similar to those
made earlier withmurine pre-B cells induced to transdifferentiate
into macrophages by C/EBPa (Bussmann et al., 2009; Di Tullio
and Graf, 2012; Xie et al., 2004).
BLaER1 Cells Commit to the Macrophage Fate after
a 3–4 Day C/EBPa Induction
An important criterion for true and stable cell reprogramming
as opposed to maintenance of the new phenotype by the
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Figure 2. Gene Expression Changes during Transdifferentiation
(A) Heatmap of K-means clustering showing two groups of probes stably down- or upregulated that showed a >-4-fold change between any two samples for at
least one time point of treatment.
(B) PCA of probes showed in the heatmap whose expression changes at least 4-fold during transdifferentiation, in comparison to the transcriptomes of normal B
cells (blue sphere) and macrophages (red sphere).
(C and D) Kinetics of expression (exp.) of selected B cell and macrophage markers during C/EBPa-induced transdifferentiation as determined by microarray.
See also Figure S3.continuous action of the transcription factor is that cells
become transgene independent (Graf and Enver, 2009).
Indeed, BLaER1 cells reprogrammed into macrophages for
8 days retained their phenotype even when the inducer was
washed out (data not shown). This raised the question as to
how long it takes to induce transgene independence. We
therefore determined the differentiation kinetics of cells treated
with E2 for 1, 2, 3, and 4 days followed by washing out andCblocking the inducer (Figure S4B). As shown in Figures 3G
and S4C, a 4 day E2 treatment was sufficient to induce
commitment to a stable macrophage phenotype. In contrast,
when cells were treated for only 2 days followed by inducer
washout, they segregated into a subset that underwent
transdifferentiation and another that regained/maintained
their B cell phenotype, whereas a 1 day treatment had no
detectable effects (Figure 3G). These experiments suggestell Reports 3, 1153–1163, April 25, 2013 ª2013 The Authors 1157
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Figure 3. During Induced Transdifferen-
tiation, Cells Become Phagocytic, Quies-
cent, and Transgene Independent
(A–D) Phagocytosis assay. Uninduced and
induced BLaER1 cells were incubated with fluo-
rescent pathogens O/N and analyzed by fluores-
cencemicroscopy and FACS. (A) Themicrographs
show dsRed E. coli bacteria in orange and nuclei
(stained with DAPI) in blue of uninduced and
induced BLaER1. (B) The FACS histograms depict
red fluorescence intensity, representing overlays
between uninduced cells and induced cells before
(blue lines) and after bacteria incubation (red lines).
(C) The micrographs show mCherry C. albicans
in red, F-actin stained with phalloidin Alexa Fluor
488 (in green), and nuclei stained with DAPI in blue
for uninduced and 4 day induced BLaER1 cells.
(D) Experiment as in (B). Blue lines represent cells
before yeast incubation and after incubation in red.
Scale bars, 10 mm.
(E) Growth curves of BLaER1 cells kept with or
without E2 for up to 8 days. Error bars represent
the SE from three independent experiments.
(F) Change of cell-cycle status in BLaER1 cells
inducedbyE2, asmeasuredbyBrdU incorporation
andpropidium iodide staining. Error bars represent
the SE from three independent experiments.
(G) Transgene independence FACS profiles show
changes in CD19 and Mac-1 expression in cells
exposed to the inducer for different times (1, 2,
and 4 days).
See also Figure S4.that the endogenous macrophage regulatory network, which
includes CEBPA, becomes activated during transdifferen-
tiation and that this network takes over in maintaining the
macrophage gene expression program, as has been shown
for pluripotency-inducing transcription factors (Stadtfeld et al.,
2008). In support of this hypothesis, we found that endogenous
CEBPA becomes activated during induction, reaching its
highest expression levels at 120 hpi (Figure S4D), roughly
coinciding with the time required to induce full transgene
independence.1158 Cell Reports 3, 1153–1163, April 25, 2013 ª2013 The AuthorsActivation of C/EBPa Impairs
the Ability of BLaER1 Cells
to Produce Tumors
Earlier experiments had shown that
Seraphina cells are tumorigenic and
cause death in 100% of inoculated,
immunodeficient Rag2/gc/ mice
with a median overall survival (OS) of
approximately 30 days (Richter-Larrea
et al., 2010). Because animals do not
tolerate treatment with E2, we first
assessed whether the nontoxic analog
4-OH tamoxifen (tamoxifen) can likewise
induce the transdifferentiation of BLaER1
cells in vitro. Indeed, treatment of
cultured BLaER1 cells with 2 mM tamox-
ifen showed similar effects as seen with100 nM E2 (Figure S5A). We then transplanted three groups of
immunodeficient Rag2/gc/ mice (n = 10 each) by intrave-
nous (i.v.) injection with 2.5 3 106 BLaER1 cells: group 1 was
injected with uninduced BLaER1 cells; group 2 received cells
treated with E2 for 8 days in vitro; and group 3 was treated
as group 2, but in addition, the mice received tamoxifen in their
drinking water to maintain the prolonged activity of C/EBPa
(Figure 4A). Tumor development was subsequently monitored
by micropositron emission tomography (microPET) imaging
of 18F-fluorodeoxyglucose (18F-FDG) uptake, an indicator of
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Figure 4. C/EBPa Impairs Tumorigenicity of
BL Cells
(A, C, and D) Schemes of experimental setups (top)
and Kaplan-Meier representation of animals’
median OS (bottom). If not stated otherwise,
experiments were performed by injecting i.v. 2.5 3
106 BLaER1 cells into tenmice per group. Asterisks
represent log rank (Mantle-Cox) test: *p% 0.05 and
**p < 0.0001.
(A) Effect of in vitro C/EBPa activation. Group 1
mice were injected with uninduced cells (green
line). Group 2 mice received cells induced for
8 days in culture (blue line), and group 3 was as
group 2, but mice were treated from 5 days before
transplantation with tamoxifen in the drinking water
(red line).
(B) MicroPET analysis of transplanted mice.
Animals were treated with 18F-FDG and assayed to
detect tumors with increased metabolic activity.
The animals belonging to group 1 exhibited liver
tumors after 20 days p.i., whereas the mice shown
in groups 2 and 3 had no liver tumors throughout
the period of examination. SUV, standardized
uptake value.
(C) Effect of in vivo C/EBPa activation. All animals
were transplanted with uninduced cells. Group 4
(green line) represents control mice, group 5 (blue
line) was treated with tamoxifen pellets starting
5 days before transplantation, and group 6 (red line)
was treated with tamoxifen pellets 10 days after
transplantation.
(D) Effect of in vivo C/EBPa activation in mice
transplanted with 53 104 uninduced BLaER1 cells.
Group 9 mice were kept untreated (green line) or
implanted with tamoxifen pellets 10 days after
transplantation (group 10, blue line).
See also Figure S5.glucose metabolism that correlates with cell proliferation. As
shown in Figures 4A and 4B, mice in group 1 (green line) devel-
oped tumors in the liver as early as 20 days postinduction (p.i.)
with a median OS of 30 ± 5 days. In contrast, mice in groups 2
and 3 (blue and red lines, respectively; p < 0.0001 for both
comparisons) showed a significantly extended median OS
(47 ± 13 days and 46 ± 4 days), with two mice in group 2 and
four in group 3 surviving until 90 days. Upon necropsy, no tumors
could be found by histopathological examination.
To determine the cellular nature of the tumors that developed
in treated mice, we analyzed the livers from moribund animals
by histology. This revealed that the tumors consisted of cells
with lymphoid morphology (Figures S5B and S5C). FACS
analyses confirmed that the livers accumulated large numbers
of CD19posMac-1neg cells (Figure S5D), further showing that
the residual tumors did not consist of myeloid cells. To test
whether these lymphoid tumors had become unresponsive
to C/EBPa activation, we placed in culture cells from a liver infil-
trated with residual tumor cells from group 2 mice. These cells,
which were CD19posMac-1neg, exhibited similar doubling times
as uninduced BLaER1 cells and could be converted into
Mac-1posCD19neg/low macrophages after E2 treatment, with
kinetics indistinguishable from the original BLaER1 cells (Fig-Cure S5E). This indicates that the residual tumors consist of
lymphoid cells and that these remained responsive to the cell
fate-instructive effects of C/EBPa.
Because the effects observed with the in-vitro-transdifferen-
tiated cells could be caused by a defect in engraftment, we
determined whether C/EBPa induction in BLaER1 cells in vivo
can likewise impair tumor formation. For this purpose, 2.5 3
106 uninduced BLaER1 cells were transplanted into untreated
mice (group 4), mice pretreated for 5 days with tamoxifen
pellets (group 5), and mice treated with tamoxifen pellets
10 days after injection (group 6). Remarkably, tamoxifen admin-
istered not only before but also after BLaER1 cell transplan-
tation significantly delayed the development of tumors (median
OS: group 4, 29 ± 3.5 days versus group 5, 34 ± 10 days, p =
0.0148; and group 4, 29 ± 3.5 days versus group 6, 32 ±
8.5 days, p = 0.0071) (Figure 4C). Similar results were obtained
in another experiment performed by treating the animals with
tamoxifen in the drinking water instead of administering pellets
(Figure S5F). To rule out a nonspecific toxicity of the inducer
on Burkitt lymphoma (BL) cells, two groups of mice (n = 5)
were injected with 2.5 3 106 Seraphina cells in the absence
(group 7) and presence (group 8) of tamoxifen pellets. The
results showed no significant difference in the median OS ofell Reports 3, 1153–1163, April 25, 2013 ª2013 The Authors 1159
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Figure 5. C/EBPa Impairs Tumorigenicity of
Pre-B-ALL Cells
(A) FACS analysis of CD19 and Mac-1 antigen
expression in RCH-ACV-tetO-CEBPa-tdTomato
cells induced by doxycycline.
(B) Histogram representing the cell size and
granularity of cells during transdifferentiation. Blue
lines represent uninduced cells (day 0); red lines
indicate induced cells (day 7).
(C) Phagocytosis assay. Micrographs show unin-
duced and induced (day 5) cells incubated with
GFP fluorescent beads. F-actin staining is shown
in red, nuclei in blue, and fluorescent beads in
green. Scale bar, 10 mm.
(D and E) Schemes of experimental setups (top)
and Kaplan-Meier representation of animals’
median OS (bottom). (D) Effect of in vitro trans-
differentiation on tumorigenicity. Group 1 mice
were injected with uninduced RCH-ACV-tetO-
CEBPa-tdTomato cells (green line), group 2 with
day 11-induced (tdTomatopos Mac-1pos) cells, and
mice were treated with doxycycline (doxy) in the
drinking water. (E) Effect of in vivo C/EBPa acti-
vation. Mice in groups 3 and 4 were injected with
uninduced RCH-ACV-tetO-CEBPa-tdTomato
cells and kept untreated (green line) or treated with
doxycycline in the drinking water starting 5 days
before injection (blue line). Asterisks represent
significance in the log rank (Mantle-Cox): **p <
0.0001.
See also Figure S6.untreated versus treated mice (28 ± 2.5 days versus 26 ±
2 days) (Figure S5G).
To determine whether C/EBPa activation is more effective
when fewer tumor cells are inoculated, we first determined the
minimum number of cells that can induce tumors. As shown in
Figure S5H, whereas 13 103 cells were innocuous, 13 104 cells
caused tumors in all animals but showed a death delay of about
20 days, and 13 105 cells killed the animals with similar kinetics
than with 1 3 106 cells. We therefore repeated the C/EBPa
activation experiments by transplanting 50 times fewer BLaER1
cells (53 104 cells per mouse). When animals were transplanted
first and treated with tamoxifen pellets 10 days later (group 10,
blue line), the survival of micewas about 7 days longer compared1160 Cell Reports 3, 1153–1163, April 25, 2013 ª2013 The Authorsto untreated animals (group 9, green line)
(median OS, 42 ± 4 days versus 35 ±
1.5 days; p < 0.0001) (Figure 4D), showing
that C/EBPa is slightly more effective in
impairing tumor formation when mice
were injected with fewer tumor cells.
A B Cell Precursor Leukemia Cell
Line Can Also Be Converted into
Macrophages with Impaired
Tumorigenicity
To determine if the observed transdif-
ferentiation induced by C/EBPa in BL
cells can be extended to leukemia cells,
we examined the well-responding RCH-ACV cell line, originally derived from a patient with a B-ALL
containing the t(1;19)(q23;p13) chromosomal translocation
generating the E2A-PBX1 fusion protein (Jack et al., 1986). For
these experiments, we used doxycycline-inducible derivatives.
For this purpose, we first generated tetracycline transactivator-
containing RCH-ACV cells. These cells were then infected with
the inducible tetO-C/EBPa-tdTomato lentivirus. The Tomato
red fluorescent-positive cells were then sorted and cultured in
the presence or absence of doxycycline. FACS analysis showed
that the doxycycline-treated B-ALL cells can be converted
into CD19negMac-1pos cells, exhibiting a macrophage-like
morphology, increased size and granularity (Figures 5A and
5B), and the acquisition of phagocytic capacity (Figures 5C
and S6A). The cells also stopped dividing after induction (Fig-
ure S6B), thus resembling in all of these parameters BLaER1
cells induced to differentiate.
To test their tumorigenic potential, two groups of
Rag2/gc/mice (n = 7) were injected with 63 104 uninduced
and doxycycline-induced, tdTomato Mac-1pos cells. All mice in
group 1 (green line) injected with uninduced cells died with
a median OS of 31 ± 1 days, whereas all mice from group 2
(blue line) injected with induced cells survived up to 90 days p.i.
(median OS not reached; p = 0.0005), at which time they were
sacrificed and found to be free of tumors (Figure 5D). To deter-
minewhether doxycycline could also inhibit tumor formation after
transplantation, two groups of ten mice each were transplanted
with 1 3 105 uninduced RCH-ACV-tetO-CEBPa-tdTomato-
expressing cells either treated with doxycycline in the drinking
water starting 5 days before injection (group 4, blue line) or kept
untreated (group 3, green line) (Figure 5E). As can be seen in Fig-
ure 5E, doxycycline treatment in vivo resulted in a delayed onset
of tumor formation and in the survival of 60% of the mice for up
to 90 days (median OS, 30 ± 1.5 days versus not reached;
p < 0.0001). This effect was not due to an unspecific effect of
doxycycline administration in vivo because delivery of the drug
to mice transplanted with the original RCH-ACV cells had no
effect (Figure S6C).
DISCUSSION
Our data have shown that the ectopic expression of C/EBPa
can induce the conversion of selected human lymphoma
and leukemia B cell lines into macrophages. The reprogrammed
cells upregulated the expression of macrophage markers,
downregulated B cell markers, exhibited increased adherence,
granularity, cell size, and phagocytic capacity, and became
quiescent. In addition, the BL cells retained their phenotype
even after the transgene was inactivated, showing that the
process observed corresponds to bona fide reprogramming.
Importantly, the tumorigenicity of transdifferentiated lymphoma
and lymphoid leukemia cell lines was impaired after transplan-
tation into immunodeficient mice, even when C/EBPa was
activated in vivo.
Are lymphoid neoplasm-derived cell lines generally suscep-
tible to the C/EBPa-induced reprogramming into macrophages?
At first sight, the answer would seem to be no because most cell
lines tested by FACS showed only a partial response, and some
did not respond at all. However, closer analysis suggests that
the degree of responsiveness is dictated by C/EBPa levels, for
the following reasons: (i) The percentage of cells exhibiting
changes of differentiation antigens by FACS was proportional
to the transgene levels, i.e., the cell subset with the highest
transgene levels showed the highest response. In addition,
silencing of CD19 appears to require lower C/EBPa levels
than Mac-1 upregulation. (ii) With one exception, no C/EBPa
protein was detectable in the four nonresponder lines, explaining
their ‘‘resistance.’’ (iii) All ‘‘partial responders’’ that downregu-
lated CD19 antigen without showing an increase in Mac-1
changed expression of the majority of myeloid and B cell
markers tested by qRT-PCR. The observed variability in the
changes of CD19 and Mac-1 antigen expression and theirCobserved reduction over time might be due to silencing of the
transgene following induction because many lines exhibited
a gradual decrease in GFP or tdTomato used as indicators of
C/EBPa expression. However, the single nonresponder with
readily detectable C/EBPa protein raises the possibility that
aside fromC/EBPa dosage, other factors might limit the suscep-
tibility of lymphoma/leukemia cells to induce lineage switching.
Here, the accumulation of DNA methylation and chromosome
rearrangements in cell lines kept in continuous culture for pro-
longed periods of time come to mind (Mestre-Escorihuela
et al., 2007). We conclude that the majority of lymphoma and
leukemia cell lines tested, which belong to a broad spectrum
of neoplasms, responds at least partially and transiently to the
lineage-reprogramming effects of C/EBPa and that a small
proportion of cells with a sustained and high-level transgene
expression undergoes a highly efficient and sustained macro-
phage transdifferentiation.
Considering the fact that human cells have been found to be
generally much more resistant to transcription factor-induced
reprogramming than mouse cells (Stadtfeld and Hochedlinger,
2010), the observed high conversion frequency of the BL and
B-ALL lines described is remarkable. Of note, however, the
induced transdifferentiation was slower by about 3–4 days
compared to mouse pre-B cell lines expressing the same induc-
ible construct (Bussmann et al., 2009).
An earlier study with mouse melanoma cells showed that
nuclear transplantation into enucleated oocytes generated cells
resembling ‘‘normal’’ embryonic stem cells. Nevertheless,
although these cells exhibited the capacity to generate chimeras
with multiple types of differentiated cells, they still also devel-
oped tumors (Hochedlinger et al., 2004). In contrast, our work
with the RCH-ACV B-ALL cell line shows that it is, in principle,
possible to completely ‘‘normalize’’ a human tumor cell line.
Residual tumors that developed in mice injected with induced
BLaER1 cells consisted entirely of B lymphoid cells. Surprisingly,
ex vivo residual tumor cells were found to be fully susceptible
to C/EBPa-induced reprogramming, ruling out the possibility
that resistant cellular variants had formed. These findings there-
fore suggest the alternative interpretation that the retrovirally
transduced C/EBPaER transgene becomes silenced in a subset
of cells in vivo, permitting the cells’ outgrowth into tumors, and
that it is reactivated when the tumor cells are placed in culture.
The BL cell line Seraphina exhibits the t(8;14)(q24;q32) chro-
mosomal translocation placing the MYC oncogene under the
control of the IGH enhancer (Toujani et al., 2009). It therefore
seemed possible that the observed C/EBPa-induced impair-
ment of tumorigenicity is due to silencing of the IGH enhancer,
as part of the extinction of the B cell program, with the ensuing
downregulation of MYC. However, this is unlikely to be the
sole explanation because the tumorigenicity of the E2A-PBX-
transformed B-ALL cell line RCH-ACV was also impaired by
C/EBPa, as was that of the Ras-transformed murine pre-B cell
HAFTL (data not shown). Here, it needs to be added that the
observed C/EBPa-induced quiescence during lymphoid cell
reprogramming likely also contributed to the inhibition of tumor
formation.
Our data represent a proof of principle for the concept that
transdifferentiation may constitute a new therapeutic approachell Reports 3, 1153–1163, April 25, 2013 ª2013 The Authors 1161
and warrant the screening for small molecules that induce the
conversion of B cell lymphomas and leukemias into macro-
phages. Such compoundsmight bemost effective when applied
in combination with treatments that cause apoptosis.
EXPERIMENTAL PROCEDURES
All the experiments performed with mice were approved by the Ethical
Committee of Animal Experimentation of the University of Navarra.
Cell Lines and Viruses
All cell lines mentioned are classified according to Drexler (2005). All leukemia
and lymphoma cell lines and derivatives were grown at 37C in 5% CO2 in
RPMI 1640 HEPES (Lonza) with 10% FBS, Pen-Strep, and L-Glutamine
(GIBCO). To produce MSCV C/EBPaER IRES GFP virus, GP2-293 packaging
cells were cotransfected with the plasmid and pVSV.G and supernatants
concentrated by ultracentrifugation. All BL cells were infected by spin infection
and expanded for a few days. GFP+ cells were sorted. To generate the clonal
cell line (BLaER1), cells were seeded singly in 96-well plates. The TetO-
C/EBPa-tdTomato plasmid was made modifying the Phage2-TetO backbone.
To produce the C/EBPa lentivirus and the rtTA puro, 293T packaging cells
were cotransfected with the plasmid VSV.G and delta 8.9, and the supernatant
was concentrated by ultracentrifugation. All the other cell lines were first
infected by spin infection with rtTA. Cells selected for puromycin resistance
were subsequently infected with the TetO-CEBPa-tdTomato lentivirus. To
produce a stable cell line expressing the transgene, cells were treated with
doxycycline for 12 hr and sorted for the tdTomato expression.
Induction of Reprogramming and Flow Cytometry
C/EBPa was induced in the BL cells by addition of 100 nM E2 (Calbiochem)
and in all the cells containing the tetO-C/EBPa-tdTomato construct by adding
2 mg/ml doxycycline (Sigma-Aldrich) and grown with 10 ng/ml of hrIL-3
(PeproTech) and 10 ng/ml hr-CSF-1 (M-CSF). Staining for cell surface antigens
was done with directly conjugated antibodies against Mac-1 (APC) and
CD19 (APC-Cy7) (BD PharMingen). DAPI or 7AAD at 1 mg/ml was used as
viability markers. Samples were analyzed on the LSRII flow cytometer (BD
Biosciences, San Diego), and data were analyzed with FlowJo software
(Tree Star, Ashland, OR, USA).
Phagocytosis Assays
Phagocytosis of E. coliwas performed as described byBussmann et al. (2009).
For phagocytosis of yeast, a colony of mCherry-labeled C. albicans (Keppler-
Ross et al., 2008) grown on YPD agar plates was isolated and expanded for
24 hr at RT in 3 ml of YPD medium. BLaER1 cells were then incubated with
300 cfu of EtOH-inactivated C. albicans per cell O/N. The phagocytosis
experiment with GFP beads (Fluoresbrite Plain YG 1.0 Micron Microspheres;
Polysciences) was performed diluting the beads in PBS and incubating them
with cells O/N. Cells were analyzed by FACS after removing free yeast/beads
by three washes with PBS.
Immunofluorescence
Cells were grown on polylysine-treated coverslips, fixed in 4% paraformalde-
hyde, permeabilized in 13 PBS, 0.5% BSA, and 0.3% Triton X-100, and incu-
bated with either Alexa Fluor 488 or 568-coupled phalloidin (Molecular Probes,
Invitrogen) for 20 min at RT in the dark and counterstained with DAPI. All
images were acquired with an SPE confocal microscope and processed
with Adobe Photoshop software.
Cell Growth Assays and Cell-Cycle Analyses
Cells were seeded in triplicate in 24-well plates and counted at 24 or 48 hr
intervals. Cell-cycle analysis was performed by BrdU (Sigma-Aldrich) incorpo-
ration and propidium iodide (Sigma-Aldrich) staining according to the Flow
Cytometry Protocols of the Cancer Research UK (http://flowcyt.salk.edu/
protocols/pibrdu.html) using a biotin anti-BrdU antibody (Abcam) and
a secondary streptavidin APC (PharMingen).1162 Cell Reports 3, 1153–1163, April 25, 2013 ª2013 The AuthorsGene Expression Profiling by Microarray
Biological duplicates of BLaER1 cells were harvested for RNA extraction at
various times after the induction. CD71+ primary CB/CCB cells from the tonsils
of two donors and macrophages differentiated from peripheral blood of
another donor cultured for 7 days with 50 ng/ml of M-CSF were used as
controls. Total RNA was extracted with the RNeasy Mini Kit (QIAGEN) and
500 ng labeled using Agilent’s QuickAmp Labeling Kit. Labeled cRNA was
hybridized to the Agilent Human SurePrint G3 8 3 60,000 oligo microarray
(G4858A-028004). The arrays were scanned on an Agilent G2565CA microar-
ray scanner at 110% PMT and 5 mm resolution. Intensity data were extracted
using the Feature Extraction software (Agilent).
Bioinformatic Analyses
Raw data from the Feature Extraction output files were corrected for back-
ground noise using the normexp method (Ritchie et al., 2007) normalized
across samples with quantile normalization. To obtain the average value for
each annotated probe (including both genes and noncoding RNAs), duplicates
were first averaged and then the most dynamic probe was selected, yielding
34,809 probes. Heatmap was generated by K-means clustering using Gene
Cluster 3.0 using probes (n = 4901) that showed a >4-fold change between
any two samples for at least one time point. PCA was carried out on the
selected data set previously described using R v.2.14.1.
Pulse Induction Experiments
BLaER1 cells were treated with E2 for various time periods and then washed
three times in PBS before adding fresh medium plus cytokines and the ER
agonist ICI (Tocris) at 100 mM/ml. They were then analyzed at consecutive
days by FACS.
Transplantations and In Vivo Induction Experiments
Cells were injected i.v. into RAG2/gc/mice, which lack T, B, and NK cells
(Traggiai et al., 2004), as described before (Richter-Larrea et al., 2010). Tamox-
ifen (Sigma-Aldrich) resuspended in ethanol was administered in the drinking
water at a final concentration of 0.5 mg/ml. A 0.5% ethanol solution was
administrated to control animals. Tamoxifen pellets (Innovative Research of
America) were implanted subcutaneously (35 mg/animal). Doxycycline
(Sigma-Aldrich) was diluted in water and administrated in the drinking water
at 4 mg/ml.
Survival analyses undertaken by constructing Kaplan-Meier curves in
the OS of the groups of study were estimated by the log rank statistical test.
Statistically significant differences are indicated with a single asterisk (*) or
double asterisk (**), and the corresponding p value is stated in the text and
figure legends.
Imaging of Tumors
MicroPET imaging as well as the 18F-FDG uptake procedure were performed
as described before (Richter-Larrea et al., 2010). Livers from sacrificed
animals were fixed, sectioned, and stained with hematoxylin eosin.
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